Experienced in Undifferentiated Pleomorphic Sarcoma

Dr. Clarence S. Adoo

Hematology Oncology | Hematology | Oncology
Honorhealth Ambulatory
10320 W Mcdowell Rd, Suite 9030, 
Avondale, AZ 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Undifferentiated Pleomorphic Sarcoma
Honorhealth Ambulatory
10320 W Mcdowell Rd, Suite 9030, 
Avondale, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Clarence Adoo is a Hematologist Oncology specialist and a Hematologist in Avondale, Arizona. Dr. Adoo is rated as an Experienced provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Breast Cancer, Multiple Myeloma, Paget Disease of the Breast, and Ovarian Carcinosarcoma. Dr. Adoo is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in AZ
Hospital Affiliations
Banner Estrella Medical Center
Banner Boswell Medical Center
Honor Health John C. Lincoln Medical Center
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
MercyCare
  • EPO
  • HMO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

HONORHEALTH AMBULATORY
10320 W Mcdowell Rd, Suite 9030, Avondale, AZ 85392
Other Locations
HONORHEALTH AMBULATORY
5750 W Thunderbird Rd, Suite C300, Glendale, AZ 85306
HONORHEALTH AMBULATORY
10510 N 92nd St, Scottsdale, AZ 85258

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Enrollment Status: Recruiting
Publish Date: April 15, 2025
Intervention Type: Drug
Study Drugs: Sacituzumab govitecan, Sacituzumab govitecan+Pembrolizumab, IMMU-132+Cisplatin, IMMU-132+Cisplatin+Avelumab
Study Phase: Phase 2
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drugs: Avelumab, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment With Checkpoint Inhibitors (CPI) or TNBC Failing Front-line Chemotherapy for Metastatic Disease
A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment With Checkpoint Inhibitors (CPI) or TNBC Failing Front-line Chemotherapy for Metastatic Disease
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Biological, Drug
Study Drugs: Imprime PGG, Pembrolizumab
Study Phase: Phase 2
Phase 2, Open-Label, Dose-Ranging Study of SPI-2012 (HM10460A) or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Phase 2, Open-Label, Dose-Ranging Study of SPI-2012 (HM10460A) or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Enrollment Status: Completed
Publish Date: April 15, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
Enrollment Status: Terminated
Publish Date: August 24, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: December 30, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

1 Total Publications

An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.
An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.
Journal: Cancer medicine
Published: October 20, 2017
Similar Doctors
Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Mahesh K. Seetharam
Hematology Oncology | Hematology | Oncology
Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Mahesh K. Seetharam
Hematology Oncology | Hematology | Oncology

Mayo Clinic Arizona

13400 E Shea Blvd, 
Scottsdale, AZ 
 (29.2 miles away)
480-301-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mahesh Seetharam is a Hematologist Oncology specialist and a Hematologist in Scottsdale, Arizona. Dr. Seetharam is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, Melanoma, Fibrosarcoma, and Bone Marrow Aspiration. Dr. Seetharam is currently accepting new patients.

Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Michael S. Gordon
Hematology Oncology | Hematology | Oncology
Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Michael S. Gordon
Hematology Oncology | Hematology | Oncology

Honorhealth Ambulatory

10460 N 92nd St, Suite 200, 
Scottsdale, AZ 
 (24.3 miles away)
855-485-4673
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Gordon is a Hematologist Oncology specialist and a Hematologist in Scottsdale, Arizona. Dr. Gordon is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Gastrointestinal Stromal Tumor, Lung Cancer, Undifferentiated Pleomorphic Sarcoma, Vertebroplasty, and Endoscopy. Dr. Gordon is currently accepting new patients.

Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Fade Mahmoud
Hematology | Oncology
Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Fade Mahmoud
Hematology | Oncology

Banner Cancer Center Specialists LLC

2946 E Banner Gateway Dr, 
Gilbert, AZ 
 (32.6 miles away)
480-256-6444
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Fade Mahmoud is a Hematologist and an Oncologist in Gilbert, Arizona. Dr. Mahmoud is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Melanoma, Bone Tumor, Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, and Orchiectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Adoo's expertise for a condition
ConditionClose
      View All 16 Advanced Conditions
      View All 118 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile